Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAK1 shRNA
- Development stage
- Preclinical
- Lead developer
- Università degli Studi di Verona
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal
01
Overview
TAK1 shRNA is an experimental short hairpin RNA (shRNA) therapeutic candidate designed to silence the expression of Transforming Growth Factor-beta-activated kinase 1 (TAK1), also known as MAP3K7. In pancreatic cancer research, TAK1 has been identified as a critical driver of chemoresistance and tumor aggressiveness by modulating the stability and oncogenic activities of the transcriptional regulators YAP and TAZ. By utilizing RNA interference (RNAi) to knockdown TAK1 expression, researchers have demonstrated significant reductions in cell proliferation, migration, and stemness in pancreatic cancer cell lines. Furthermore, silencing TAK1 has been shown to revert intrinsic chemoresistance, potentiating the cytotoxic effects of standard chemotherapeutic agents such as nab-paclitaxel and gemcitabine. This approach highlights the potential of targeting the TAK1/YAP/TAZ axis as a therapeutic strategy for aggressive pancreatic ductal adenocarcinoma.
- Other names
- shTAK1shTAK-1shTAK 1TAK1-silencing shRNATAK-1-silencing shRNATAK 1-silencing shRNA
02
Targets
TAK1 (Transforming growth factor beta–activated kinase 1)
Beyond the preview
Go deeper on TAK1 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAK1 shRNA.